$2.5M Public Offering Priced at $0.65, Deep Discount to Market
SLXN is trading near its 52-week low of $1.02 (5.9% above the low) on elevated volume (2.9× avg).
Summary
Silexion Therapeutics priced a public offering of 3.85 million shares with series E warrants at $0.65 per unit, a 40% discount to the $1.08 market price. Gross proceeds are $2.5 million, intended to fund the SIL204 clinical trial and general corporate purposes. The offering is highly dilutive given the company's $1.1 million market cap, effectively more than doubling the share count. This follows a going concern warning in May and a 1-for-10 reverse split, underscoring the company's urgent need for capital. The deep discount and warrant overhang signal weak demand and significant pressure on the stock.
At the time of this announcement, SLXN was trading at $1.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $1.02 to $82.90. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.